Drug-Coated Balloons For Coronary Artery Disease Global Market Opportunities And Strategies To 2035

Drug-Coated Balloons For Coronary Artery Disease Market Definition

Drug-coated balloons (DCBs) for coronary artery disease (CAD) refer to a category of interventional cardiovascular devices designed to treat narrowed or blocked coronary arteries through percutaneous coronary intervention (PCI). The primary purpose of DCBs in CAD treatment is to restore proper blood flow in diseased coronary arteries while minimizing the need for permanent implants like stents. The drug-coated balloons for coronary artery disease market consists of sales, by entities (organizations, sole traders, or partnerships) that are used by interventional cardiologists and are deployed during PCI procedures commonly performed in hospitals, cardiac catheterization labs and, in some cases, ambulatory surgical centers. They are used at the time of balloon angioplasty, where the device is introduced via catheter, navigated to the lesion, inflated to dilate the artery and concurrently release the drug to prevent re-narrowing.

Drug-Coated Balloons For Coronary Artery Disease Market Segmentation

The drug-coated balloons for coronary artery disease market is segmented by type, by end-user.

By Drug Type –
The drug-coated balloons for coronary artery disease market is segmented by drug type into:

• a) Paclitaxel-Coated DCBs
• b) Limus-Coated DCBs

The paclitaxel-coated DCBs market was the largest segment of the drug-coated balloons for coronary artery disease market segmented by drug type, accounting for 96.0% or $474.5 million of the total in 2025. Going forward, the limus-coated DCBs segment is expected to be the fastest growing segment in the drug-coated balloons for coronary artery disease market segmented by drug type, at a CAGR of 12.7% during 2025-2030.

By End-User –
The drug-coated balloons for coronary artery disease market is segmented by end-user into:

• a) Hospitals
• b) Cardiac Catheterization Labs
• c) Ambulatory Surgical Centers
• d) Other End-Users

The hospitals market was the largest segment of the drug-coated balloons for coronary artery disease market segmented by end user, accounting for 51.1% or $252.8 million of the total in 2025. Going forward, the cardiac catheterization labs segment is expected to be the fastest growing segment in the drug-coated balloons for coronary artery disease market segmented by end user, at a CAGR of 14.1% during 2025-2030.

By Geography - The drug-coated balloons for coronary artery disease market is segmented by geography into:

o Asia Pacific
• • China
• • India
• • Japan
• • Australia
• • Indonesia
• • South Korea
o North America
• • USA
• • Canada
o South America
• • Brazil
o Western Europe
• • France
• • Germany
• • UK
• • Italy
• • Spain
o Eastern Europe
• • Russia
o Middle East
o Africa

Western Europe was the largest region in the drug-coated balloons for coronary artery disease market, accounting for 55.7% or $275.4 million of the total in 2025. It was followed by Asia Pacific, North America and then the other regions. Going forward, the fastest-growing regions in the drug-coated balloons for coronary artery disease market will be Africa and Middle East where growth will be at CAGRs of 19.1% and 18.4% respectively. These will be followed by Latin America and North America where the markets are expected to grow at CAGRs of 18.0% and 14.6% respectively.

Drug-Coated Balloons For Coronary Artery Disease Market Drivers

The key drivers of the drug-coated balloons for coronary artery disease market include: Increasing Burden Of Diabetes And Obesity During the forecast period, the surge in the increasing burden of diabetes and obesity will propel the growth of the drug-coated balloons for coronary artery disease market. Rising levels of obesity and type 2 diabetes contribute directly to the development of atherosclerosis, endothelial dysfunction and arterial plaque buildup, all of which significantly heighten the risk of coronary artery disease. Individuals with diabetes and obesity experience accelerated vascular damage driven by insulin resistance, elevated blood glucose, chronic inflammation and abnormal lipid metabolism, factors that greatly increase the likelihood of requiring coronary interventions. Moreover, the global shift toward sedentary lifestyles, high-calorie diets and rapid urbanization continues to push obesity and diabetes rates upward across many regions. As countries face growing metabolic health challenges and a larger population enters high-risk cardiovascular categories, the demand for effective, minimally invasive coronary treatment options such as drug-coated balloons rises substantially, thereby driving the growth of the drug-coated balloons for coronary artery disease market. The surge in the increasing burden of diabetes and obesity the forecast period in 2025 is 1.50%.

Drug-Coated Balloons For Coronary Artery Disease Market Restraints

The key restraints on the drug-coated balloons for coronary artery disease market include: Lack Of Universal Guideline Support Lack of universal guideline support is restricting the growth of the drug-coated balloons for coronary artery disease market during the forecast period. The absence of widely accepted, standardized clinical guidelines for the use of drug-coated balloons (DCBs) in coronary interventions limits physician confidence and adoption, particularly in regions where cardiology protocols rely heavily on traditional stenting or bypass procedures. Without clear consensus and guideline backing, cardiologists may hesitate to recommend DCB therapy and payers or insurers may be reluctant to reimburse it, reducing market uptake. Moreover, regulatory bodies and hospital committees often prefer established procedures over newer technologies without guideline endorsement, which slows integration of DCBs into mainstream treatment protocols. As a result, despite clinical potential, the adoption of drug-coated balloons remains constrained in many markets, thereby restraining the growth of the drug-coated balloons for coronary artery disease market. Growth affected by lack of universal guideline support during the forecast period in 2025 is -2.40%.

Drug-Coated Balloons For Coronary Artery Disease Market Competitive Landscape

Major Competitors are:

B. Braun Melsungen AG

Boston Scientific Corporation

BIOTRONIK SE & Co. KG

Cordis Corporation (MedAlliance)

Meril Life Sciences Pvt. Ltd

Other Competitors Include:

Acotec Scientific Holdings., Ltd.

Medtronic plc

Blue Sail Medical

OrbusNeich Medical Company Ltd.

MicroPort Scientific Corporation

Shenqi Medical

Sichuan Xingtai Pule

Shanghai MicroPort Medical (Group) Co., Ltd.

BrosMed

Concept Medical

Nano Therapeutics Pvt Ltd.

Envision Scientific

Philips

DK Medical (Dissolve)

Translumina

Minvasys

Eurocor GmbH

iVascular

Abbott Cardiovascular

BD (Becton, Dickinson and Company)

Concept Medical

EUROCOR S.A

iVascular

Philips (Koninklijke Philips N.V.)

Terumo Corporation

Concept Medical

Drug-Coated Balloons For Coronary Artery Disease Market Trends

Major trends shaping the drug-coated balloons for coronary artery disease market include: Emergence Of Sirolimus-Eluting Drug-Coated Balloons As Advanced Solutions For Coronary Intervention Major companies in the drug-coated balloons for coronary artery disease market are focusing on the development of sirolimus-eluting drug-coated balloons (DCBs) designed to provide enhanced vessel healing and broaden treatment options for both de novo lesions and in-stent restenosis. These advancements emphasize improved drug-release profiles, reduced inflammatory response and greater procedural flexibility, while offering clinicians implant-free solutions that align with evolving interventional strategies. For instance, in October 2025, Cordis, a US-based global cardiovascular device manufacturer, showcased new clinical data on its sirolimus-eluting balloon at the TCT 2025 conference, highlighting its performance in large, randomized studies evaluating outcomes in patients with both de novo coronary artery disease and in-stent restenosis. The reported results demonstrated non-inferiority to standard drug-eluting stent treatments, while also showing the potential to eliminate the need for permanent implants in a significant portion of patients. By utilizing advanced sirolimus-delivery technology and robust multi-trial clinical evidence, the company aims to support wider adoption of DCB solutions and to meet the evolving requirements of global coronary intervention markets. Expansion Of Clinical Studies Evaluating Drug-Coated Balloons Against Standard Care In Coronary Interventions Key companies in the drug-coated balloons for coronary artery disease market are focusing on initiating large-scale comparative clinical studies to evaluate the performance of drug-coated balloons (DCBs) against standard care treatments, such as drug-eluting stents and conventional balloon angioplasty. These initiatives aim to strengthen clinical evidence, broaden therapeutic indications and provide more refined, patient-specific intervention options for complex coronary lesions. For instance, in March 2024, Boston Scientific, a US-based global medical device manufacturer, received FDA approval for its AGENT Drug-Coated Balloon, marking the first coronary DCB approved in the United States for the treatment of coronary in-stent restenosis. The device is designed to address limitations associated with conventional balloon angioplasty by delivering a targeted therapeutic dose of paclitaxel to the vessel wall, thereby reducing the likelihood of recurrent restenosis. By leveraging advanced coating technology and extensive clinical evidence, the company aims to provide clinicians with an effective and less-invasive treatment option that aligns with the evolving needs of both domestic and international coronary intervention markets.

Opportunities And Recommendations In The Drug-Coated Balloons For Coronary Artery Disease Market

Opportunities – The top opportunities in the drug-coated balloons for coronary artery disease market segmented By Drug Type will arise in the paid service membership segment, which will gain $1,255.0 million of global annual sales by 2030. The top opportunities in the drug-coated balloons for coronary artery disease market segmented by application will arise in the mobile devices segment, which will gain $1,250.1 million of global annual sales by 2030. The top opportunities in the drug-coated balloons for coronary artery disease market segmented by end user will arise in the individual segment, which will gain $1,078.6 million of global annual sales by 2030. The drug-coated balloons for coronary artery disease market size will gain the most in the USA at $508.1 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the drug-coated balloons for coronary artery disease companies to focus on sirolimus-based innovation backed by clinical evidence, focus on large-scale comparative evidence to expand clinical adoption, focus on next-generation DCB versatility across lesion types, focus on dual-track DCB portfolios balancing scale and innovation, focus on channel expansion into specialized and outpatient cardiac care, focus on value-based and setting-specific pricing discipline, focus on evidence-led clinical promotion to drive adoption, focus on procedure-focused promotion across care settings, focus on shifting growth toward specialized and outpatient care settings.